Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNICORN study
2022-501308-90-00Phase 2Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Apr 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of botensilimab, sotorasib, trastuzumab deruxtecan, durvalumab, nivolumab and 4 more in colorectal cancer (CRC) (10 cohorts), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Major pathological response rate. Planned start Apr 2023; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-501308-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501308-90-00.